StockNews.AI
CLDI
StockNews.AI
202 days

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

1. Calidi invites investors to a webinar on Feb 5, 2025. 2. CFO Andrew Jackson will discuss their innovative cancer therapies. 3. Highlights include CLD-400, CLD-201, and CLD-101 treatment platforms. 4. Groundbreaking technology aims to enhance efficacy and safety in cancer treatment. 5. A live Q&A will provide further insights into their developments.

6m saved
Insight
Article

FAQ

Why Bullish?

The upcoming webinar and product insights may increase investor interest in CLDI.

How important is it?

The webinar's potential to drive investor engagement creates a noteworthy impact opportunity.

Why Short Term?

Investor sentiment could change quickly following the webinar and responses.

Related Companies

CLDI
SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD. PhD, who will share insight into the company’s groundbreaking cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced cancer treatment. Highlights will include overviews of Calidi’s lead programs, such as its CLD-400 systemic platform targeting metastatic cancers, CLD-201 for advanced solid tumors and CLD-101 for high-grade glioma. A live Q&A session with the leadership team will follow the presentation. To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_qCp0OhjDSSaqiz3QsW9C_A#/registration Questions can be pre-submitted to CLDI@redchip.com or online during the live event. About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies, are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com. Forward-Looking StatementsThis press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company’s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024, and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time. Corporate Communications:Dave Gentry, CEORedChip Companies, Inc.1-407-644-4256CLDI@redchip.com    Source: Calidi Biotherapeutics, Inc.

Related News